C-2PZ1Rejuvenation Technologies
telomere extension, modified mRNA, lipid nanoparticles
repairingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-2PZ1
C-2PZ1C-2PZ1telomere extension, modified mRNA, lipid nanoparticles
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Rejuvenation Technologies telomere extension, modified mRNA, lipid nanoparticles
Rejuvenation is developing technologies to rewind cellular mechanisms of aging, including therapeutic telomere extension. Its approach uses modified mRNA to temporarily activate telomerase in specific cells, with proprietary lipid nanoparticle delivery for targeted treatment. The company lists preclinical Phase I programs for pulmonary fibrosis, chronic liver disease, and a hematologic indication.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Rejuvenation Technologies — Early mechanism · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (4 programs at preclinical).…
Source: Deterministic